Showing results (121-130 of 337) with videos related to

Sort By:
Pageof 34
Cancer Research and Treatment|April 29, 2016
Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program CohortMinkyu Jung, Jeeyun Lee, Tae Min Kim, et al.
Cancer Research and Treatment|December 5, 2022
Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor TreatmentYoon Jung Jang, Dong-Gon Hyun, Wonjun Ji, et al.
Plos One|April 17, 2020
Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasisDong-Gon Hyun, Chang-Min Choi, Dae Ho Lee, et al.
Cancer Letters|August 12, 2017
The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancerKang-Seo Park, Hannah Yang, Junyoung Choi, et al.
Oncotarget|August 27, 2015
Transcriptome analysis indicates TFEB1 and YEATS4 as regulatory transcription factors for drug resistance of ovarian cancerYi Rang Kim, Mi Sung Park, Ki Hwan Eum, et al.
Translational Lung Cancer Research|July 23, 2021
Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective studyMyeong Geun Choi, Chang-Min Choi, Dae Ho Lee, et al.
Diabetes & Metabolism Journal|June 30, 2024
Association of Succinate and Adenosine Nucleotide Metabolic Pathways with Diabetic Kidney Disease in Patients with Type 2 Diabetes MellitusInha Jung, Seungyoon Nam, Da Young Lee, et al.
Cancer Medicine|July 25, 2023
Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinomaDae Ho Lee, Hye Ryun Kim, Bhumsuk Keam, et al.
Leukemia Research|August 6, 2010
BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicityJeong Eun Kim, Dae Ho Lee, Changhoon Yoo, et al.
Investigational New Drugs|September 17, 2009
Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trialByeong-Bae Park, Won Seog Kim, Hyeon Seok Eom, et al.
Pageof 34